TLSI
HealthcareTriSalus Life Sciences, Inc.
$6.11
+$0.01 (+0.16%)
Jan 5, 2026
Price History (1Y)
Analysis
TriSalus Life Sciences, Inc. is a healthcare company within the medical devices industry, with a market capitalization of $305.28M and approximately 110 employees. The company's revenue for the trailing twelve months (TTM) was $40.21M. The financial health of TriSalus Life Sciences, Inc. is characterized by significant losses. Net income for the TTM was -$70,828,000, with an operating margin of -77.9% and a profit margin of -98.4%. The company's return on assets (ROA) was -61.1%, indicating that it generated negative earnings from its assets. The balance sheet shows $22.69M in cash and $34.12M in debt. The valuation context for TriSalus Life Sciences, Inc. is marked by a forward P/E ratio of -12.22 and an EV/EBITDA ratio of -10.35. The company's revenue growth rate was 57.4% year-over-year (YoY), but earnings growth data is not available. Dividend information is also not applicable, as the dividend yield and payout ratio are both N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Visit website →Key Statistics
- Market Cap
- $305.28M
- P/E Ratio
- N/A
- 52-Week High
- $7.95
- 52-Week Low
- $3.42
- Avg Volume
- 162.46K
- Beta
- 0.43
Company Info
- Industry
- Medical Devices
- Exchange
- NGM
- Country
- United States
- Employees
- 110